Radiotherapy for superficial esophageal cancer

Okawa, Tomohiko; Tanaka, Makiko; Kita, Midori; Kaneyasu, Yuko; Karasawa, Kumiko; Ide, Hiroko; Murata, Yoko; Yamada, Akihiro

doi:10.1016/0360-3016(94)90372-7

Cited by 18 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[7][8][9][10][11][12][13][14] In our series, the 5-year overall and cause-specific survivals of patients with stage I disease were 50.4% and 91.2%, respectively, despite almost all patients (88%) with submucosal cancer. Our results are comparable to those of the previous studies.…”

Section: Discussionmentioning

confidence: 84%

Treatment Outcomes of Radiotherapy for Patients With Stage I Esophageal Cancer

Sasaki

Nakamura

Shioyama

et al. 2007

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 84%

Treatment Outcomes of Radiotherapy for Patients With Stage I Esophageal Cancer

Sasaki

Nakamura

Shioyama

et al. 2007

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…It has been reported that the prognosis of ESCC in patients with T1 tumors who underwent chemoradiation therapy or surgery was similar (8). Therefore, it is increasingly more important to select for surgery only those patients who will benefit from the same.…”

Section: Discussionmentioning

confidence: 99%

Expression of ECRG4 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma

Mori

Ishiguro²,

Kuwabara³

et al. 2007

Oncol Rep

View full text Add to dashboard Cite

Abstract. In this study, we examined the expression of esophageal cancer-related gene 4 (ECRG4) mRNA and evaluated its clinical significance in esophageal squamous cell carcinoma (ESCC). ECRG4 mRNA expression was quantified by real-time RT-PCR in 63 ESCC and corresponding normal esophageal mucosal samples. ECRG4 mRNA expression levels were significantly lower in ESCC tissues compared with corresponding normal esophageal mucosa (P<0.0001), in patients with locally invasive T2-4 tumors compared with less invasive T1 tumors (P=0.0229) and in stage 4 tumors compared with stage 0-3 tumors (P=0.0120). Furthermore, low ECRG4 mRNA expression levels were associated with significantly shorter survival after surgery compared with high ECRG4 mRNA expression levels (P=0.0150) in ESCC patients. On the basis of multivariate analysis, we conclude that ECRG4 mRNA expression level could be a candidate for an independent prognostic factor for ESCC patients.

show abstract

“…8 Okawa et al have reported that patients treated with external radiotherapy and ICRT boost showed better local control but no survival benefit in comparison to those treated with external radiotherapy alone. 4 In contrast, it was recently reported by Nemoto et al that ICRT could not improve the local control or the survival in those with either mucosal or submucosal esophageal cancer. 11 Consistent with the result reported by Nemoto et al, we also were unable in this study to show a difference in the clinical outcome between the patients treated with external radiotherapy alone and those treated with external radiother- Approximately half of the patients in this series received combined chemotherapy.…”

Section: Discussionmentioning

confidence: 83%

Clinical Results of Radiation Therapy for Stage I Esophageal Cancer

Shioyama¹,

Nakamura²,

Sasaki³

et al. 2005

American Journal of Clinical Oncology

View full text Add to dashboard Cite

From 1992 through 2001, 29 patients with stage I esophageal cancer were treated with radiation therapy. All patients had squamous cell carcinoma. Seventeen patients were treated with radiotherapy alone, and 12 were treated with a combination of chemotherapy and radiotherapy. Most of the chemotherapy regimens included cisplatin and/or 5-fluorouracil (5-FU). Twelve patients were treated with intracavitary irradiation (low-dose rate: 6, high-dose rate: 6) after external radiotherapy. Median fraction and total doses of external radiotherapy given were 2.0 Gy and 60.6 Gy, respectively. Median doses of intracavitary irradiation were 18 Gy/6 fractions in low-dose-rate brachytherapy and 13.5 Gy/4.5 fractions in high-dose-rate brachytherapy. The 5-year overall survival rate was 62%. The 5-year local control rate was 44%. Of the 29 patients, 9 had in-field recurrence in the esophagus and 1 had recurrence in the esophagus outside of the irradiated field. Of 9 patients with in-field local recurrence, 1 also developed mediastinal lymph node metastases and 1 had distant metastasis. Radiation therapy is an effective treatment modality for stage I esophageal cancer.

show abstract

Radiotherapy for superficial esophageal cancer

Cited by 18 publications

References 16 publications

Treatment Outcomes of Radiotherapy for Patients With Stage I Esophageal Cancer

Treatment Outcomes of Radiotherapy for Patients With Stage I Esophageal Cancer

Expression of ECRG4 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma

Clinical Results of Radiation Therapy for Stage I Esophageal Cancer

Contact Info

Product

Resources

About